FPF
LRMR icon

FNY Partners Fund’s Larimar Therapeutics LRMR Stock Holding History

FNY Partners Fund’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-333
Closed -$14K – 659
2017
Q2 		$14K Sell
333
-84
-20% -$4.3K ﹤0.01% 369
2017
Q1 		$23K Buy
+417
New +$20.7K ﹤0.01% 910

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

FNY Partners Fund's LRMR Position: Q3 2017 in Review

FNY Partners Fund sold out of Larimar Therapeutics (LRMR) in Q3 2017, closing a stake of 333 shares — an estimated $14K sold.

FNY Partners Fund first reported a position in LRMR in Q1 2017 and held it in 2 quarters. The position peaked at $23K in Q1 2017. 62 funds tracked by Wall St. Rank hold LRMR as of Q3 2017.

  • FNY Partners Fund reported no remaining Larimar Therapeutics position as of Q3 2017 after selling out during the quarter.
  • FNY Partners Fund sold 333 Larimar Therapeutics shares in Q3 2017, an estimated $14K.
  • FNY Partners Fund first reported a position in Larimar Therapeutics in Q1 2017 and held it in 2 quarters.
  • FNY Partners Fund's Larimar Therapeutics position peaked at $23K in Q1 2017.
  • 62 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.